EP4473122A4 - Omikron-coronavirus-impfstoffkonstrukte und verfahren zur herstellung und verwendung davon - Google Patents

Omikron-coronavirus-impfstoffkonstrukte und verfahren zur herstellung und verwendung davon

Info

Publication number
EP4473122A4
EP4473122A4 EP23750408.9A EP23750408A EP4473122A4 EP 4473122 A4 EP4473122 A4 EP 4473122A4 EP 23750408 A EP23750408 A EP 23750408A EP 4473122 A4 EP4473122 A4 EP 4473122A4
Authority
EP
European Patent Office
Prior art keywords
omikron
manufacture
coronavirus vaccine
vaccine constructions
constructions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23750408.9A
Other languages
English (en)
French (fr)
Other versions
EP4473122A2 (de
Inventor
Michael Diamond
Igor Dmitriev
Ahmed Hassan
David Curiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of EP4473122A2 publication Critical patent/EP4473122A2/de
Publication of EP4473122A4 publication Critical patent/EP4473122A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23750408.9A 2022-02-02 2023-02-02 Omikron-coronavirus-impfstoffkonstrukte und verfahren zur herstellung und verwendung davon Pending EP4473122A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305979P 2022-02-02 2022-02-02
US202263375803P 2022-09-15 2022-09-15
US202263384075P 2022-11-16 2022-11-16
US202263434815P 2022-12-22 2022-12-22
PCT/US2023/061878 WO2023150638A2 (en) 2022-02-02 2023-02-02 Omicron coronavirus vaccine constructs and methods of making and using same

Publications (2)

Publication Number Publication Date
EP4473122A2 EP4473122A2 (de) 2024-12-11
EP4473122A4 true EP4473122A4 (de) 2026-03-04

Family

ID=87552962

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23750408.9A Pending EP4473122A4 (de) 2022-02-02 2023-02-02 Omikron-coronavirus-impfstoffkonstrukte und verfahren zur herstellung und verwendung davon

Country Status (7)

Country Link
EP (1) EP4473122A4 (de)
JP (1) JP2025508676A (de)
KR (1) KR20240137110A (de)
CN (1) CN120282795A (de)
AU (1) AU2023216258A1 (de)
CA (1) CA3243465A1 (de)
WO (1) WO2023150638A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN116987184B (zh) * 2023-09-26 2024-01-12 北京百普赛斯生物科技股份有限公司 新型冠状病毒bq.1.1突变株特异性抗体及其应用
WO2025202543A1 (en) * 2024-03-28 2025-10-02 Rokote Laboratories Finland Oy A vaccine composition comprising an adenoviral vector and an adenoviral vector delivery enhancing agent
WO2025250851A1 (en) * 2024-05-29 2025-12-04 Washington University Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716928C (en) * 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA3167833A1 (en) * 2020-02-14 2021-08-19 Bertrand Victor Gilbert GEORGES Coronavirus immunogenic compositions and uses thereof
WO2021247567A1 (en) * 2020-06-01 2021-12-09 Washington University Coronavirus vaccine constructs and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AFKHAMI SAM ET AL: "Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2", CELL, ELSEVIER, AMSTERDAM NL, vol. 185, no. 5, 9 February 2022 (2022-02-09), pages 896, XP086981415, ISSN: 0092-8674, [retrieved on 20220209], DOI: 10.1016/J.CELL.2022.02.005 *
HASSAN AHMED O ET AL: "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2", CELL, ELSEVIER, AMSTERDAM NL, vol. 183, no. 1, 19 August 2020 (2020-08-19), pages 169, XP086280364, ISSN: 0092-8674, [retrieved on 20200819], DOI: 10.1016/J.CELL.2020.08.026 *
HASSAN AHMED O. ET AL: "A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques", CELL REPORTS MEDICINE, vol. 2, no. 4, 1 April 2021 (2021-04-01), pages 100230, XP093345815, ISSN: 2666-3791, DOI: 10.1016/j.xcrm.2021.100230 *
MACHHI JATIN ET AL: "Nanocarrier vaccines for SARS-CoV-2", ADVANCED DRUG DELIVERY REVIEWS, vol. 171, 1 April 2021 (2021-04-01), Amsterdam , NL, pages 215 - 239, XP055846786, ISSN: 0169-409X, DOI: 10.1016/j.addr.2021.01.002 *
MENDON�A SAMIR ANDRADE ET AL: "Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic", NPJ VACCINES, vol. 6, no. 1, 5 August 2021 (2021-08-05), XP093070871, Retrieved from the Internet <URL:https://www.nature.com/articles/s41541-021-00356-x> DOI: 10.1038/s41541-021-00356-x *

Also Published As

Publication number Publication date
AU2023216258A1 (en) 2024-08-01
WO2023150638A2 (en) 2023-08-10
EP4473122A2 (de) 2024-12-11
JP2025508676A (ja) 2025-04-10
WO2023150638A3 (en) 2023-09-14
CN120282795A (zh) 2025-07-08
CA3243465A1 (en) 2023-08-10
KR20240137110A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
EP4473122A4 (de) Omikron-coronavirus-impfstoffkonstrukte und verfahren zur herstellung und verwendung davon
EP4017568A4 (de) Katheter sowie verfahren zur herstellung und verwendung
EP3960720A4 (de) Zur dentalen verwendung geeigneter zirkoniumoxid-calcinierter körper und verfahren zur herstellung davon
EP4438722A4 (de) Menschliche induzierbare t-zelle und verfahren zur herstellung davon
EP4125748A4 (de) Makuladentor und verfahren zur verwendung und herstellung davon
EP4245913A4 (de) Keramikpapier und verfahren zur herstellung davon
EP4206220C0 (de) Proinsulinglargin und verfahren zur herstellung von insulinglargin daraus
EP4330362C0 (de) Verwendung und verfahren zur herstellung von mono-rhamnolipiden
EP4330418C0 (de) Verwendung und verfahren zur herstellung von mono-rhamnolipiden
EP4502148A4 (de) Universalzelle und verfahren zur herstellung davon
EP4342866C0 (de) Faserzementprodukt und verfahren zur herstellung davon
EP4369995A4 (de) Schrotstrohhalme und verfahren zur herstellung und verwendung davon
EP4499055A4 (de) Abietane und verfahren zur herstellung und verwendung davon
EP4621917A4 (de) Elektrodenanordnung und verfahren zur herstellung davon
EP4505243A4 (de) Tamm-polaritonemitter und verfahren zur herstellung und verwendung davon
EP4410963A4 (de) Verfahren zur herstellung von zellmasse einschliesslich hypophysengewebe und zellmasse
EP4241294A4 (de) Anschlussanordnungen und verfahren zur verwendung und herstellung davon
EP4321614A4 (de) Verfahren zur herstellung von oligodendrozyten und verwendung
EP4139366A4 (de) Biokompatibles material und verfahren zur herstellung und verwendung davon
EP4123728A4 (de) Photodiode und verfahren zur herstellung davon
EP4122617A4 (de) Stahlelement und verfahren zur herstellung davon
EP4452151A4 (de) Fussgelenkorthese und verfahren zur herstellung und verwendung
EP4456823C0 (de) Sterilisationshülle und verfahren zur herstellung und verwendung
EP4501231A4 (de) Bioelektrode und verfahren zur herstellung davon
EP4483885C0 (de) Zusammensetzung, verfahren zur herstellung davon und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240826

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260129

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/86 20060101AFI20260123BHEP

Ipc: A61K 39/00 20060101ALI20260123BHEP

Ipc: A61K 39/12 20060101ALI20260123BHEP

Ipc: C07K 14/005 20060101ALI20260123BHEP

Ipc: C07K 14/165 20060101ALI20260123BHEP

Ipc: A61P 31/12 20060101ALI20260123BHEP

Ipc: A61P 31/14 20060101ALI20260123BHEP